CEO Mark Toland will discuss the soft tissue open surgery field and the growth potential for the applications of robotic microsurgery
JACKSONVILLE, Fla.–(BUSINESS WIRE)–MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the company has been invited to participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 8-11, 2024. This marks the second consecutive year that MMI has presented at the conference. The J.P. Morgan Healthcare Conference is one of the largest healthcare investment symposiums in the industry and connects global leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
MMI’s Chief Executive Officer, Mark Toland, will present on Tuesday, January 9, at 9:30am PST at the Westin St. Francis Hotel in the Mission Bay Meeting Room. His presentation will cover the current state of the soft tissue open surgery field, recent company milestones, and the potential for innovation through robotics. A Q&A session will follow the presentation.
For more information about the J.P. Morgan Healthcare Conference, visit https://www.jpmorgan.com/about-us/events-conferences/health-care-conference. To learn more about MMI, visit https://mmimicro.com.
About MMI
MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair, lymphatic repair, and peripheral nerve repair. The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use. MMI is backed by international medtech investors including Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
Contacts
Investor Relations:
Lisa Croke
[email protected]
Media:
Dan Ventresca
Matter Health for MMI
[email protected]